Article

Dendritic cell therapy in advanced gastric cancer: a promising new hope?

Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi 221005, U.P., India.
Surgical Oncology (impact factor: 2.44). 04/2012; 21(3):164-71. DOI:10.1016/j.suronc.2012.03.003 pp.164-71
Source: PubMed

ABSTRACT Advanced gastric cancer carries a very poor prognosis when the tumor becomes unresectable. Even with the best currently available chemotherapy regimens the survival rate remains dismal. A recent breakthrough in the treatment paradigm has been the approval of trastuzumab, a monoclonal antibody, in HER2-positive metastatic gastric cancer. A large number of trials are underway using dendritic cells (DCs) in a number of human malignancies and do show a ray of hope in management of these patients. This review attempts to summarize tumor immunology and the current data regarding use of DCs in gastric cancer therapy.

0 0
 · 
0 Bookmarks
 · 
56 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Advanced gastric cancer
 
current data
 
DCs
 
gastric cancer therapy
 
HER2-positive metastatic gastric cancer
 
human malignancies
 
monoclonal antibody
 
patients
 
poor prognosis
 
ray
 
survival rate
 
treatment paradigm
 
trials